Deprenorm MV extended-release tablets 35 mg No. 60
A country
Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Trimetazidine
Compound
1 tablet contains: trimetazidine dihydrochloride 35 mg. Excipients: calcium hydrogen phosphate dihydrate - 34.6 mg, hyprolose (hydroxypropylcellulose) - 6 mg, hypromellose (hydroxypropylmethylcellulose) - 64 mg, copovidone - 4.2 mg, colloidal silicon dioxide (aerosil) - 6.4 mg, magnesium stearate - 0.8 mg, microcrystalline cellulose - 59 mg. Shell composition: selecoate AQ-01673 - 7 mg (hypromellose (hydroxypropyl methylcellulose) - 2.8 mg, macrogol 400 (polyethylene glycol 400) - 0.7 mg, macrogol 6000 (polyethylene glycol 6000) - 0.7 mg , aluminum varnish based on crimson dye (Ponceau 4R) (E124) - 0.7 mg, titanium dioxide - 2.1 mg). Long-acting tablets, film-coated, pink, round, biconvex. Minor roughness is allowed. Almost white in cross section.
pharmachologic effect
A drug that improves myocardial metabolism. Has an antihypoxic effect in stable angina. Directly influencing cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). Supports myocardial contractility, prevents a decrease in intracellular ATP content and creatine phosphate. In conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content caused by myocardial ischemia and reperfusion. Prevents the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of the electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic myocardial damage. Trimetazidine reduces the frequency of angina attacks (nitrate consumption decreases), after 2 weeks of use of the drug tolerance to physical activity increases, sharp fluctuations in blood pressure decrease. Reduces dizziness and tinnitus. In case of vascular pathology of the eyes, it improves the functional activity of the retina.
Indications for use
— IHD: prevention of attacks of stable angina (as part of complex therapy); — chorioretinal disorders with an ischemic component; — cochleo-vestibular disorders of an ischemic nature (dizziness, tinnitus, hearing impairment).
Mode of application
The drug is taken orally with meals. The recommended dose is 1 tablet. 2 times a day (morning and evening). The duration of treatment is determined individually.
Side effect
The frequency of side effects noted when taking trimetazidine is given in the following gradation: very often (>1/10); often (>1/100, 1/1000, 1/10,000, Contraindications—severe renal failure (CC Overdose Data on cases of overdose are limited. Treatment: in case of overdose, symptomatic therapy should be carried out.
special instructions
The drug is not intended for the relief of angina attacks, for the initial course of treatment of stable angina or myocardial infarction. If angina attacks develop, the therapy should be reconsidered. Effect on the ability to drive vehicles and operate machinery. The use of the drug does not affect the ability to drive a vehicle and perform work requiring increased speed of psychomotor reactions.
Dispensing conditions in pharmacies
On prescription
Buy Deprenorm MV film-coated tablets 35 mg No. 60 in pharmacies
Instructions for use Deprenorm MV
Buy Deprenorm MV TB 35mg
Dosage forms: extended-release film-coated tablets 35 mg, modified-release film-coated tablets 35 mg Manufacturers Canonpharma Production (Russia) Group Various antianginal agents Composition Active substance - trimetazidine. International nonproprietary name Trimetazidine Synonyms Angiosil retard, Angital, Antisten, Antisten MV, Vero-Trimetazidine, Medarum 20, Medarum MV, PreBRuctal, Predizin, Preductal MV, Rimekor, Rimekor MV, Triducard, Trimectal MV, Trimet, Trimetazidine, Trimetazidine, Trimetazidine MV , Trimetazidine-Biocom MV, Trimetazidine-Teva, Trimetazidine-FPO Pharmacological action Antianginal, antihypoxic, cytoprotective, metabolic. Directly affects cardiomyocytes and neurons of the brain, optimizing their metabolism and functions. Supports myocardial contractility, prevents intracellular depletion of ATP and phosphocreatinine. In conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular potassium content. Completely and quickly absorbed from the gastrointestinal tract, easily passes through histohematic barriers. The half-life is about 6 hours. It is excreted unchanged by the kidneys. For angina pectoris, it reduces the frequency of attacks; after 2 weeks of treatment, tolerance to physical activity increases, and drops in blood pressure decrease. Improves hearing and the results of vestibular tests in patients with ENT pathologies, reduces dizziness and tinnitus. In case of vascular pathology of the eye, it restores the functional activity of the retina. Indications for use: Coronary heart disease, angina pectoris, ischemic cardiomyopathy (as part of complex therapy), chorioretinal vascular disorders, tinnitus, dizziness (vascular disorders, Meniere's disease). Contraindications Hypersensitivity, severe liver dysfunction, renal failure, children under 18 years of age, pregnancy, lactation. Side effects Nausea, pain in the epigastric region, allergic reactions (itching). Other: headache, feeling of palpitations. Interaction No information available. Method of administration and dosage Deprenorm MV is prescribed orally with meals. The recommended dosage regimen is 2 tablets (70 mg) per day, in 2 divided doses. The duration of treatment is determined individually. Overdose No information available. Special instructions No information available. Storage conditions List B. In a dry place, protected from light.
Deprenorm MV table. with mod. release 35mg N30
Registration Certificate Holder
KANOPHARMA PRODUCTION (Russia)
Dosage form
Medicine - Deprenorm® MR (Deprenorm MR)
Description
Extended-release film-coated tablets
pink, round, biconvex; slight roughness is allowed; almost white in cross section.
1 tab.
trimetazidine dihydrochloride 35 mg
Excipients
: calcium hydrogen phosphate dihydrate - 34.6 mg, hyprolose (hydroxypropylcellulose) - 6 mg, hypromellose (hydroxypropylmethylcellulose) - 64 mg, copovidone - 4.2 mg, colloidal silicon dioxide (aerosil) - 6.4 mg, magnesium stearate - 0.8 mg, microcrystalline cellulose - 59 mg .
Shell composition:
selecoate AQ-01673 - 7 mg (hypromellose (hydroxypropyl methylcellulose) - 2.8 mg, macrogol 400 (polyethylene glycol 400) - 0.7 mg, macrogol 6000 (polyethylene glycol 6000) - 0.7 mg, aluminum varnish based on crimson dye (Ponceau 4R) (E124) - 0.7 mg, titanium dioxide - 2.1 mg).
10 pieces. — cellular contour packages (1) — cardboard packs. 10 pieces. — contour cell packaging (2) — cardboard packs. 10 pieces. — cellular contour packages (3) — cardboard packs. 10 pieces. — contour cell packaging (6) — cardboard packs. 30 pcs. — cellular contour packages (1) — cardboard packs. 30 pcs. — contour cell packaging (2) — cardboard packs. 30 pcs. — cellular contour packages (3) — cardboard packs. 30 pcs. — contour cell packaging (4) — cardboard packs.
Indications
- IHD: prevention of attacks of stable angina (as part of complex therapy);
- chorioretinal disorders with an ischemic component;
- cochleo-vestibular disorders of ischemic nature (dizziness, tinnitus, hearing impairment).
Contraindications for use
- severe renal failure (creatinine clearance <15 ml/min);
- severe liver dysfunction;
- pregnancy;
- lactation period (breastfeeding);
- children and adolescents under 18 years of age (efficacy and safety have not been established);
- hypersensitivity to the components of the drug.
pharmachologic effect
A drug that improves myocardial metabolism. Has an antihypoxic effect in stable angina. Directly affecting cardiomyocytes and neurons of the brain, it optimizes their metabolism and function.
The cytoprotective effect is due to an increase in energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation).
Supports myocardial contractility, prevents a decrease in the intracellular content of ATP and creatine phosphate. In conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content caused by myocardial ischemia and reperfusion. Prevents the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of the electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic damage to the myocardium.
Trimetazidine reduces the frequency of angina attacks (nitrate consumption decreases), after 2 weeks of using the drug, exercise tolerance increases, and sharp fluctuations in blood pressure decrease. Reduces dizziness and tinnitus.
In case of vascular pathology of the eye, it improves the functional activity of the retina.
Drug interactions
There is no information on drug interactions with Deprenorm® MB.
Dosage regimen
The drug is taken orally with meals.
Recommended dose: 1 tablet. 2 times/day (morning and evening).
The duration of treatment is determined individually.
Overdose
Data on overdose cases are limited.
Treatment:
in case of overdose, symptomatic therapy should be carried out.
Side effect
The frequency of side effects noted when taking trimetazidine is given in the following gradation: very often (>1/10); often (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10,000, <1/1000); very rare (<1/10,000, including isolated reports).
From the side of the central nervous system:
often - dizziness, headache; very rarely - extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.
From the cardiovascular system:
rarely - orthostatic hypotension, “flushes” of blood to the facial skin.
From the digestive system:
often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting.
Allergic reactions:
often - skin rash, itching, urticaria.
Others
: often - asthenia.
special instructions
The drug is not intended for the relief of angina attacks or for the initial course of treatment of stable angina or myocardial infarction.
If angina attacks develop, therapy should be reconsidered.
Effect on the ability to drive vehicles and operate machinery.
The use of the drug does not affect the ability to drive a vehicle and perform work that requires an increased speed of psychomotor reactions.
Storage conditions
The drug should be stored out of the reach of children, in a dry place, protected from light, at a temperature not exceeding 25°C.
Best before date
Shelf life: 3 years.
Use during pregnancy and breastfeeding
Restrictions during pregnancy - Contraindicated. Restrictions when breastfeeding - Contraindicated.
The drug is contraindicated during pregnancy due to the lack of clinical data on the safety of its use.
It is not known whether trimetazidine is excreted in breast milk. If it is necessary to use the drug during lactation, breastfeeding should be stopped.
Use for renal impairment
Restrictions for impaired renal function - With caution.
Contraindicated in severe renal failure (creatinine clearance <15 ml/min).
Use for liver dysfunction
Restrictions for liver dysfunction - With caution.
Contraindicated in cases of severe liver dysfunction.
Use in children
Restrictions for children - Contraindicated.
Contraindication: children and adolescents under 18 years of age (efficacy and safety have not been established).
Terms of sale
The drug is available with a prescription.
Contacts for inquiries
KANOPHARMA PRODUCTION CJSC (Russia)
141100 Moscow region. Shchelkovo, st. Zarechnaya, 105 Tel. 739-38-86 Fax
